Blog
-
-
After Imfinzi’s double flop, AstraZeneca walks away from FDA bladder cancer nod
-
Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients
-
A gene therapy pipeline takes shape for a cluster of rare diseases
-
ASCO GU: Bristol Myers touts first-in-class Opdivo win in muscle-invasive bladder cancer
-
FDA weighs tighter restrictions for Pfizer’s Xeljanz on the heels of safety red flags
-
Gene therapy for hemophilia: So close, yet so far away
-
ONLY 25 SPOTS LEFT! Asked & Answered | Covid-19 Vaccines
-
Could Stem Cell Therapy Be a Breakthrough Against MS?
-
US watchdog flags top drugmakers for unsupported price hikes